Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study

被引：49

作者：

Thomas, AL

Cox, G

Sharma, RA

Steward, WP

Shields, F

Jeyapalan, K

Muller, S

O'Byrne, KJ ^{[1
]}

机构：

[1] Leicester Royal Infirm, Dept Oncol, Leicester LE1 5WW, Leics, England

[2] Glenfield Hosp, Dept Radiol, Leicester, Leics, England

[3] Leicester Royal Infirm, Dept Pathol, Leicester LE1 5WW, Leics, England

来源：

EUROPEAN JOURNAL OF CANCER | 2000年 / 36卷 / 18期

关键词：

gemcitabine; nun-small cell lung cancer; paclitaxel; pneumonitis;

D O I：

10.1016/S0959-8049(00)00341-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The aim of this phase I/II dose escalating study was to establish the maximum tolerated dose (MTD) of gemcitabine and paclitaxel given in combination in non-small cell lung cancer (NSCLC). 12 patients with stage IIIB and IV NSCLC received paclitaxel administered intravenously over 1 h followed by gemcitabine given over 30 min on days 1, 8 and 15 every 28 days. Pneumonitis was the principal side-effect observed with 4 patients affected. Of these, 1 experienced grade 3 toxicity after one cycle of treatment and the others had grade 2 toxicity. All 4 cases responded to prednisolone. No other significant toxicities were observed. Of the 8 evaluable patients, 3 had a partial response and 2 had minor responses. The study was discontinued due to this dose-limiting toxicity. The combination of paclitaxel and gemcitabine shows promising antitumour activity in NSCLC, however, this treatment schedule may predispose to pneumonitis. (C) 2000 Elsevier Science Ltd. All rights reserved.

引用

页码：2329 / 2334

页数：6

共 26 条

[1]

ALBERTI W, 1995, BRIT MED J, V311, P899

[2] Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: A multicenter phase II study [J].

Androulakis, N ;

Kouroussis, C ;

Kakolyris, S ;

Tzannes, S ;

Papadakis, E ;

Papadimitriou, C ;

Geroyianni, A ;

Georgopoulou, T ;

Dimopoulou, I ;

Souglakos, J ;

Kotsakis, A ;

Vardakis, N ;

Hatzidaki, D ;

Georgoulias, V .

ANNALS OF ONCOLOGY, 1998, 9 (10) :1127-1130

[3] Cancer, cigarette smoking and premature death in Europe: A review including the Recommendations of European Cancer Experts Consensus Meeting, Helsinki, October 1996 [J].

Boyle, P .

LUNG CANCER, 1997, 17 (01) :1-60

[4] ADVANCED BREAST-CANCER - A PHASE-II TRIAL WITH GEMCITABINE [J].

CARMICHAEL, J ;

POSSINGER, K ;

PHILLIP, P ;

BEYKIRCH, M ;

KERR, H ;

WALLING, J ;

HARRIS, AL .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (11) :2731-2736

[5]

Carney DN, 1999, ONCOLOGY-NY, V13, P51

[6] Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life [J].

Cullen, MH ;

Billingham, LJ ;

Woodroffe, CM ;

Chetiyawardana, AD ;

Gower, NH ;

Joshi, R ;

Ferry, DR ;

Rudd, RM ;

Spiro, SG ;

Cook, JE ;

Trask, C ;

Bessell, E ;

Connolly, CK ;

Tobias, J ;

Souhami, RL .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3188-3194

[7]

DEBRAUD F, 1999, P ASCO, V18, pA500

[8] Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma [J].

Dunsford, ML ;

Mead, GM ;

Bateman, AC ;

Cook, T ;

Tung, K .

ANNALS OF ONCOLOGY, 1999, 10 (08) :943-947

[9]

EINHORN LH, 1998, P AN M AM SOC CLIN, V17, pA207

[10] Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: A phase I-II study [J].

Frasci, G ;

Panza, N ;

Cornella, P ;

Nicolella, GP ;

Natale, M ;

Manzione, L ;

Bilancia, D ;

Cioffi, R ;

Maiorino, L ;

De Cataldis, G ;

Belli, M ;

Micillo, E ;

Mascia, V ;

Massidda, B ;

Lorusso, V ;

De Lena, M ;

Carpagnano, F ;

Contu, A ;

Pusceddu, G ;

Comella, G .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2316-2325

← 1 2 3 →